Gilead Sciences, whose hepatitis C dynasty has been slipping, has won approval for its next-gen hepatitis B treatment.

Word is Pfizer is considering selling or spinning off its consumer health operations and that it could bring in $14 billion or more.

AstraZeneca’s top line got hit hard in Q3, and much of the pain came from plummeting Crestor sales. But the British drugmaker had underperformance in a couple…

Drugs aren’t helping John Paulson much these days as shares in Valeant, Shire, Mylan, Allergan and Teva, take big cuts out of his hedge funds.  

Regeneron capped a rough four weeks last Friday with news that sarilumab, its anti-inflammatory blockbuster hopeful, had been knocked aside by the FDA. But…

Allergan’s third-quarter numbers weren’t good. But neither was the way the company talked about them, one analyst says, and that’s the most worrisome part of…

Q3 was not a pretty one for Allergan, which recorded EPS and revenue misses and lowered its full-year guidance. But that doesn’t mean the company isn’t a “…

Another quarter, another slump for Gilead’s hepatitis C franchise, with sales down 31%. Despite better-than-expected overall revenue, market-watchers zeroed on…

Financials